Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DEB-TACE, Lenvatinib, and Pucotenlimab for Unresectable Intrahepatic Cholangiocarcinoma
NCT06192784Phase 2Recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2023
- Primary completion
- Jan 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pucotenlimab in intrahepatic cholangiocarcinoma (ICC), sponsored by Tongji Hospital. Primary endpoint: Number of Patients Amendable to Curative Surgical Interventions at 3 years. Started Dec 2023; status: recruiting.
02
Drugs
pucotenlimab
03
Conditions
intrahepatic cholangiocarcinoma (ICC)
Beyond the preview
Go deeper on NCT06192784.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06192784.